BillionToOne has launched Northstar Origin, a liquid biopsy add-on that predicts cancer tissue of origin from cell-free DNA, and expands its genomic profiling panel to 102 genes.
HPV self-testing at an opioid treatment program raised cervical cancer screening rates, with 90% of eligible patients opting in, according to a study in JAMA Network Open. The approach targets high-risk, underserved populations.
A Labcorp survey of 148 US pathologists reports rising cancer rates are driving demand for digital pathology and genomic testing, but reimbursement and workforce shortages remain significant barriers to technology adoption.
Caris Life Sciences has launched in-house PTEN IHC testing to identify prostate cancer patients eligible for FDA-approved, biomarker-guided therapy, supporting precision treatment for PTEN-deficient mAPMN/S prostate cancer.
Read More
Cancer Cell Diagnostics has launched the CellSight DNA test, a liquid biopsy that isolates intact circulating tumor cells for genomic profiling from a single blood draw, enabling analysis of over 500 genes and key biomarkers.
Read More
Concert has issued a coverage policy deeming the EsoGuard Esophageal DNA Test medically necessary for eligible patients, with multiple client health plans now adopting the policy.
Read More
SOPHiA GENETICS and AstraZeneca have signed a multi-year agreement to develop and deploy decentralized companion diagnostics for solid tumors and blood cancers, aiming to expand local lab access to precision oncology testing.
Read More
Labcorp is offering nationwide access to Roche’s FDA-approved VENTANA PTEN (SP218) RxDx Assay, the first IHC companion diagnostic to identify PTEN protein loss in prostate cancer and guide eligibility for combination therapy with capivasertib.
Read More
Clinical labs are adopting broader cancer diagnostics—including whole-genome sequencing and multi-omic testing—to deliver more comprehensive molecular insights and improve disease monitoring.
Read More
Researchers at Johns Hopkins validated an AI-powered blood test that accurately detects liver cancer in diverse populations, using the DELFI platform to analyze cell-free DNA fragments.
Read More
GenomOncology and PacBio have introduced an integrated workflow for somatic whole-genome sequencing in oncology, combining PacBio’s HiFi WGS analysis with GenomOncology’s reporting platform for standardized clinical lab reporting.
Read More
A Johns Hopkins study finds that a single liquid biopsy within nine weeks of immunotherapy start can predict long-term survival in advanced lung cancer, providing results months earlier than standard imaging.
Read More
A Cedars-Sinai study in JAMA Network Open reports women testing negative for BRCA mutations but with a family cancer history face a 25% lifetime breast cancer risk, underscoring the importance of family history in risk assessment.
Read More
A peer-reviewed study validates Astrin Biosciences’ Certitude test, which uses proteomics and machine learning to detect early-stage breast cancer with 92.6% sensitivity and 92.3% specificity.
Read More
10x Genomics and Lausanne University Hospital have begun a multi-year study using single cell and spatial technologies to identify biomarkers predicting treatment response in patients with advanced solid tumors.
Read More
YD Bio and Numia Health have launched a six-month pilot in British Columbia to evaluate cross-border blood-based cancer testing, supporting up to 50 patient episodes with laboratory analysis performed at a CLIA-certified U.S. facility.
Read More
Nabsys and Indiana University School of Medicine have launched a multi-year collaboration to develop electronic genome mapping applications for acute myeloid leukemia and myelodysplastic syndromes.
Read More
RNA-based testing improves detection of MET exon 14 skipping in NSCLC, identifying mutations missed by DNA-only assays, according to new research. Findings may impact eligibility for targeted therapies.
Read More